Empresa Shin Nippon Biomedical Laboratories, Ltd. BOERSE MUENCHEN
Acciones
YB3
JP3379950003
Biotecnología e investigación médica
En tiempo real
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
8,2 EUR | -2,38 % |
|
+1,82 % | -22,22 % |
Resumen de negocios
Ventas por actividad
JPY en millones | 2023 | Peso | 2024 | Peso | Delta |
---|---|---|---|---|---|
Contract Research Organization
97,0
%
| 23 924 | 95,4 % | 25 661 | 97,0 % | +7,26 % |
Medipolis
1,8
%
| 601 | 2,4 % | 478 | 1,8 % | -20,52 % |
Others
1,1
%
| 549 | 2,2 % | 300 | 1,1 % | -45,29 % |
Translational Research
0,0
%
| 16 | 0,1 % | 12 | 0,0 % | -29,19 % |
Ventas por región
JPY en millones | 2023 | Peso | 2024 | Peso | Delta |
---|---|---|---|---|---|
Japan
67,3
%
| 18 515 | 73,8 % | 17 812 | 67,3 % | -3,80 % |
United States
16,9
%
| 3 843 | 15,3 % | 4 482 | 16,9 % | +16,62 % |
South Korea
14,2
%
| - | - | 3 763 | 14,2 % | - |
Other
1,5
%
| 2 733 | 10,9 % | 393 | 1,5 % | -85,61 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 01/09/81 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 01/05/02 |
Terumasa Hirai
CMP | Compliance Officer | - | 01/04/84 |
Shunji Haruta
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/01 |
Ken Takanashi
COO | Chief Operating Officer | 60 | 01/12/02 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 01/04/17 |
Kyomi Nagatoshi
IRC | Investor Relations Contact | - | 01/02/02 |
Hiroyuki Izumi
PRN | Corporate Officer/Principal | - | 01/04/92 |
Masakazu Suda
AUD | Comptroller/Controller/Auditor | 62 | 01/08/90 |
Toshihiko Makino
AUD | Comptroller/Controller/Auditor | - | 01/04/05 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Ichiro Nagata
BRD | Director/Board Member | 38 | 01/04/17 |
Sales & Marketing | 64 | 01/11/02 | |
Ken Takanashi
COO | Chief Operating Officer | 60 | 01/12/02 |
Corporate Officer/Principal | 56 | 01/06/99 | |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 01/05/02 |
Hideshi Tsusaki
PRN | Corporate Officer/Principal | 57 | 01/04/96 |
Director/Board Member | 66 | 01/06/15 | |
Director/Board Member | 68 | 01/06/15 | |
Tsuyoshi Hanada
BRD | Director/Board Member | - | 26/06/20 |
Keiko Toya
BRD | Director/Board Member | 60 | 01/06/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 41 632 400 | 19 291 331 ( 46,34 %) | 469 ( 0,001127 %) | 46,34 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
WAVE LIFE SCIENCES LTD. 53.83% | 2 100 000 | 53.83% | 12 978 000 $ |
TMS CO., LTD. 3.56% | 1 433 320 | 3.56% | 1 915 417 $ |
400 | 0.00% | 3 457 $ |
Información de la empresa
Shin Nippon Biomedical Laboratories, Ltd.
St. Luke's Tower, 28/F 8-1 Akashi-cho
104-0044, Tokyo
+81 9 9294 3389
http://www.snbl.co.jp![Dirección Shin Nippon Biomedical Laboratories, Ltd.(YB3)](https://cdn.zonebourse.com/static/address/160189296.png)
Sector
Ventas por actividad
Ventas por región
![Consenso](/images/consensus_flch.gif)
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+16,59 % | 45,51 mil M | |
-9,89 % | 38,52 mil M | |
+38,08 % | 38,13 mil M | |
+27,12 % | 30,74 mil M | |
-8,64 % | 26,03 mil M | |
+11,81 % | 25,92 mil M | |
+45,08 % | 14,13 mil M | |
+32,85 % | 12,73 mil M | |
-7,19 % | 11,29 mil M |
- Bolsa de valores
- Acciones
- Acción 2395
- Acción YB3
- Empresa Shin Nippon Biomedical Laboratories, Ltd.